Table 2.
Tumor and treatment characteristics
| Variable | Frequency (%) |
|---|---|
| Affected side | |
| Right | 6 (60) |
| Left | 4 (40) |
| Affected quadrant | |
| Upper outer | 8 (80) |
| Lower outer | 1 (10) |
| Central | 1 (10) |
| Tumor stage | |
| cT1a | 0 (0) |
| cT1b | 3 (30) |
| cT1c | 5 (50) |
| cT2 | 2 (20) |
| Histopathologic subtype | |
| NST | 7 (70) |
| ILC | 2 (20) |
| Atypical medullary carcinoma | 1 (10) |
| Grading | |
| G1 | 1 (10) |
| G2 | 5 (50) |
| G3 | 4 (40) |
| Receptor status | |
| ER+/PR+/HER2- | 5 (50) |
| ER+/PR-/HER2- | 1 (10) |
| ER+/PR+/HER2+ | 1 (10) |
| ER-/PR-/HER2- | 3 (30) |
| Chemotherapy | |
| No | 5 (50) |
| Yes | 5 (50) |
| Neoadjuvant | 2 (20) |
| Adjuvant | 3 (30) |
| WBRT | |
| Yes | 7 (70) |
| No | 2 (20) |
| Refused due to impaired healing | 1 (10) |
| Reason not clear | 1 (10) |
| Stopped | 1 (10 ) |
NST carcinoma of no special type, ILC invasive lobular carcinoma, ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor 2, WBRT whole-breast radiotherapy